Memgen Overview
- Year Founded
-
2004
- Status
-
Private
- Employees
-
7
- Latest Deal Type
-
Series A2
- Latest Deal Amount
-
$950K
- Investors
-
1
Memgen General Information
Description
Developer of viral immunotherapies designed to treat multiple cancer types. The company develops clinical-stage therapies using viral vectors to activate dendritic cells and induce anti-tumor immune responses, enabling patients with cancers like bladder, melanoma, lymphoma, lung, and liver to overcome resistance to chemotherapy.
Contact Information
Website
www.memgenbio.comCorporate Office
- 12 Greenway Plaza
- Suite 1100
- Houston, TX 77046
- United States
Corporate Office
- 12 Greenway Plaza
- Suite 1100
- Houston, TX 77046
- United States
Memgen Timeline
Memgen Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC (Series A2) | 10-Dec-2024 | $950K | Completed | Clinical Trials - Phase 1 | ||
| 7. Later Stage VC (Series A1) | 30-Jun-2023 | Completed | Clinical Trials - Phase 1 | |||
| 6. Later Stage VC (Series A) | 30-Nov-2021 | Completed | Pre-Clinical Trials | |||
| 5. Debt - General | 24-Jun-2020 | Completed | Pre-Clinical Trials | |||
| 4. Angel (individual) | 23-Sep-2019 | Completed | Pre-Clinical Trials | |||
| 3. Angel (individual) | 04-Dec-2018 | Completed | Pre-Clinical Trials | |||
| 2. Capitalization | 25-Sep-2004 | $6.9M | $6.9M | Completed | Startup | |
| 1. University Spin-Out | 01-Jan-2004 | Completed | Clinical Trials - Phase 1 |
Memgen Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-1 | ||||||||
| Series A |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Memgen Comparisons
Industry
Financing
Details
Memgen Competitors (32)
One of Memgen’s 32 competitors is Inovio Pharmaceuticals, a Corporation company based in Plymouth Meeting, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| Allogene Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Genocea Biosciences | Formerly VC-backed | Cambridge, MA | ||||
| Sorrento Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Ayala Pharmaceuticals | Corporation | Wilmington, DE |
Memgen Patents
Memgen Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025194221-A1 | A pulmonary vaccine to prevent tuberculosis | Pending | 22-Mar-2024 | ||
| EP-4444334-A2 | Oncolytic virus boosts t cell response for effective til therapy | Pending | 07-Dec-2021 | ||
| EP-4444334-A4 | Oncolytic virus boosts t cell response for effective til therapy | Pending | 07-Dec-2021 | ||
| US-20230270784-A1 | Oncolytic virus boosts t cell response for effective til therapy | Pending | 07-Dec-2021 | ||
| WO-2023108003-A2 | Oncolytic virus boosts t cell response for effective til therapy | Inactive | 07-Dec-2021 | A61K35/17 |
Memgen Signals
Memgen Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| University of California, San Diego | University | Minority |
Memgen FAQs
-
When was Memgen founded?
Memgen was founded in 2004.
-
Where is Memgen headquartered?
Memgen is headquartered in Houston, TX.
-
What is the size of Memgen?
Memgen has 7 total employees.
-
What industry is Memgen in?
Memgen’s primary industry is Drug Discovery.
-
Is Memgen a private or public company?
Memgen is a Private company.
-
What is Memgen’s current revenue?
The current revenue for Memgen is .
-
How much funding has Memgen raised over time?
Memgen has raised $36.9M.
-
Who are Memgen’s investors?
University of California, San Diego has invested in Memgen.
-
Who are Memgen’s competitors?
Inovio Pharmaceuticals, Allogene Therapeutics, Genocea Biosciences, Sorrento Therapeutics, and Ayala Pharmaceuticals are some of the 32 competitors of Memgen.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process